Strasberg B, Sagie A, Rechavia E, Katz A, Ovsyscher I A, Sclarovsky S, Agmon J
Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel.
Cardiovasc Drugs Ther. 1989 Jan;2(6):801-6. doi: 10.1007/BF00133211.
Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5-10 mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.
三名患者因心房颤动伴快速心室反应及宽预激QRS波群( Wolff - Parkinson - White综合征)被送至急诊室。所有三名患者均接受了静脉注射维拉帕米(5 - 10毫克)。第一名患者发生心室颤动,需要多次除颤;第二名患者出现严重血流动力学恶化,需要紧急心脏复律;第三名患者心室反应明显增加,然而,没有血流动力学损害。维拉帕米用于患有Wolff - Parkinson - White综合征和心房颤动的患者时可能会导致有害结果。因此,在这些患者中使用维拉帕米应被视为绝对禁忌。